A detailed history of Diligent Investors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Diligent Investors, LLC holds 10,898 shares of BMY stock, worth $634,590. This represents 0.14% of its overall portfolio holdings.

Number of Shares
10,898
Previous 10,498 3.81%
Holding current value
$634,590
Previous $435,000 29.43%
% of portfolio
0.14%
Previous 0.12%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$39.66 - $51.75 $15,863 - $20,700
400 Added 3.81%
10,898 $563,000
Q2 2024

Jul 15, 2024

SELL
$40.25 - $52.99 $5,635 - $7,418
-140 Reduced 1.32%
10,498 $435,000
Q1 2024

May 03, 2024

SELL
$47.98 - $54.4 $11,995 - $13,600
-250 Reduced 2.3%
10,638 $576,000
Q4 2023

Jan 10, 2024

SELL
$48.48 - $57.85 $11,247 - $13,421
-232 Reduced 2.09%
10,888 $558,000
Q3 2023

Nov 03, 2023

SELL
$57.89 - $64.73 $7,352 - $8,220
-127 Reduced 1.13%
11,120 $645,000
Q1 2023

May 10, 2023

BUY
$65.71 - $74.53 $22,932 - $26,010
349 Added 3.2%
11,247 $779,000
Q4 2022

Jan 20, 2023

SELL
$68.48 - $81.09 $13,696 - $16,218
-200 Reduced 1.8%
10,898 $0
Q3 2022

Oct 14, 2022

SELL
$0.13 - $76.84 $41 - $24,281
-316 Reduced 2.77%
11,098 $789,000
Q2 2022

Jul 13, 2022

SELL
$72.62 - $79.98 $10,529 - $11,597
-145 Reduced 1.25%
11,414 $879,000
Q1 2022

Apr 26, 2022

SELL
$61.48 - $73.72 $24,223 - $29,045
-394 Reduced 3.3%
11,559 $844,000
Q4 2021

Jan 21, 2022

SELL
$53.63 - $62.52 $13,192 - $15,379
-246 Reduced 2.02%
11,953 $745,000
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $12,072 - $13,146
-195 Reduced 1.57%
12,199 $815,000
Q1 2021

Apr 23, 2021

BUY
$59.34 - $66.74 $2,610 - $2,936
44 Added 0.36%
12,394 $782,000
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $17,437 - $19,759
302 Added 2.51%
12,350 $766,000
Q3 2020

Nov 09, 2020

SELL
$57.43 - $63.64 $32,045 - $35,511
-558 Reduced 4.43%
12,048 $726,000
Q2 2020

Jul 09, 2020

BUY
$54.82 - $64.09 $26,971 - $31,532
492 Added 4.06%
12,606 $741,000
Q1 2020

Apr 29, 2020

SELL
$46.4 - $67.43 $20,833 - $30,276
-449 Reduced 3.57%
12,114 $675,000
Q4 2019

Jan 13, 2020

SELL
$49.21 - $64.19 $13,237 - $17,267
-269 Reduced 2.1%
12,563 $806,000
Q3 2019

Oct 22, 2019

SELL
$42.77 - $50.71 $21,598 - $25,608
-505 Reduced 3.79%
12,832 $651,000
Q2 2019

Aug 01, 2019

SELL
$44.62 - $49.34 $23,559 - $26,051
-528 Reduced 3.81%
13,337 $605,000
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $10,106 - $12,051
-224 Reduced 1.59%
13,865 $661,000
Q4 2018

Jan 17, 2019

SELL
$48.76 - $63.23 $1,462 - $1,896
-30 Reduced 0.21%
14,089 $732,000
Q3 2018

Oct 26, 2018

SELL
$55.19 - $62.25 $45,310 - $51,107
-821 Reduced 5.5%
14,119 $877,000
Q2 2018

Jul 23, 2018

SELL
$50.53 - $62.98 $16,068 - $20,027
-318 Reduced 2.08%
14,940 $827,000
Q1 2018

Apr 23, 2018

SELL
$59.92 - $68.98 $17,796 - $20,487
-297 Reduced 1.91%
15,258 $965,000
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $179 - $196
3 Added 0.02%
15,555 $953,000
Q3 2017

Nov 09, 2017

SELL
$55.23 - $63.74 $79,973 - $92,295
-1,448 Reduced 8.52%
15,552 $991,000
Q2 2017

Aug 11, 2017

BUY
N/A
17,000
17,000 $947,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Diligent Investors, LLC Portfolio

Follow Diligent Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diligent Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Diligent Investors, LLC with notifications on news.